NCT03549338 2020-09-28
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Symphogen A/S
Phase 2 Terminated
Clinical Trials
5 trialsNCT02540161 2020-08-05
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Duke University
Phase 2 Completed
NCT02083653 2019-04-16
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Symphogen A/S
Phase 2 Completed
NCT01417936 2018-10-15
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Symphogen A/S
Phase 2 Completed
NCT02965417 2017-02-01
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Symphogen A/S
Phase 2 Withdrawn